Chimerix Statistics
Total Valuation
Exagen has a market cap or net worth of $202.43 million. The enterprise value is $197.70 million.
Important Dates
The last earnings date was Tuesday, July 29, 2025, before market open.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Exagen has 22.00 million shares outstanding. The number of shares has increased by 6.55% in one year.
| Current Share Class | 22.00M |
| Shares Outstanding | 22.00M |
| Shares Change (YoY) | +6.55% |
| Shares Change (QoQ) | +13.62% |
| Owned by Insiders (%) | 8.71% |
| Owned by Institutions (%) | 24.16% |
| Float | 13.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.98 |
| Forward PS | 2.80 |
| PB Ratio | 9.62 |
| P/TBV Ratio | 9.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.95, with a Debt / Equity ratio of 1.20.
| Current Ratio | 4.95 |
| Quick Ratio | 4.30 |
| Debt / Equity | 1.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.03 |
Financial Efficiency
Return on equity (ROE) is -87.94% and return on invested capital (ROIC) is -19.94%.
| Return on Equity (ROE) | -87.94% |
| Return on Assets (ROA) | -16.24% |
| Return on Invested Capital (ROIC) | -19.94% |
| Return on Capital Employed (ROCE) | -28.97% |
| Revenue Per Employee | $273,777 |
| Profits Per Employee | -$78,977 |
| Employee Count | 215 |
| Asset Turnover | 1.09 |
| Inventory Turnover | 7.22 |
Taxes
In the past 12 months, Exagen has paid $49,000 in taxes.
| Income Tax | 49,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +275.51% in the last 52 weeks. The beta is 1.62, so Exagen's price volatility has been higher than the market average.
| Beta (5Y) | 1.62 |
| 52-Week Price Change | +275.51% |
| 50-Day Moving Average | 7.41 |
| 200-Day Moving Average | 5.04 |
| Relative Strength Index (RSI) | 77.85 |
| Average Volume (20 Days) | 428,091 |
Short Selling Information
The latest short interest is 922,602, so 4.19% of the outstanding shares have been sold short.
| Short Interest | 922,602 |
| Short Previous Month | 484,525 |
| Short % of Shares Out | 4.19% |
| Short % of Float | 6.78% |
| Short Ratio (days to cover) | 3.58 |
Income Statement
In the last 12 months, Exagen had revenue of $58.86 million and -$16.98 million in losses. Loss per share was -$0.89.
| Revenue | 58.86M |
| Gross Profit | 34.98M |
| Operating Income | -14.04M |
| Pretax Income | -17.28M |
| Net Income | -16.98M |
| EBITDA | -12.30M |
| EBIT | -14.04M |
| Loss Per Share | -$0.89 |
Full Income StatementBalance Sheet
The company has $30.03 million in cash and $25.30 million in debt, giving a net cash position of $4.74 million or $0.22 per share.
| Cash & Cash Equivalents | 30.03M |
| Total Debt | 25.30M |
| Net Cash | 4.74M |
| Net Cash Per Share | $0.22 |
| Equity (Book Value) | 21.03M |
| Book Value Per Share | 0.96 |
| Working Capital | 40.69M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.37 million and capital expenditures -$615,000, giving a free cash flow of -$15.98 million.
| Operating Cash Flow | -15.37M |
| Capital Expenditures | -615,000 |
| Free Cash Flow | -15.98M |
| FCF Per Share | -$0.73 |
Full Cash Flow StatementMargins
Gross margin is 59.42%, with operating and profit margins of -23.85% and -28.85%.
| Gross Margin | 59.42% |
| Operating Margin | -23.85% |
| Pretax Margin | -28.76% |
| Profit Margin | -28.85% |
| EBITDA Margin | -20.89% |
| EBIT Margin | -23.85% |
| FCF Margin | n/a |
Dividends & Yields
Exagen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.55% |
| Shareholder Yield | -6.55% |
| Earnings Yield | -8.39% |
| FCF Yield | -7.90% |
Analyst Forecast
The average price target for Exagen is $11.75, which is 27.72% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.75 |
| Price Target Difference | 27.72% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 13.68% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Exagen has an Altman Z-Score of -4.98 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.98 |
| Piotroski F-Score | 4 |
